Physician profile
Mark Lee Craft
NPI 1689657926
$4,060.03
in general payments reported to CMS, 2019-2025
36 companies · $18.85 in 2025
The $18.85 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $259 · 2021: $333 · 2022: $771 · 2023: $1,017 · 2024: $459 · 2025: $18.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,476 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,475.86 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $648.14 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $385.15 | 2019-2023 | Mounjaro |
| Boston Scientific Corporation | $383.70 | 2019-2023 | Rotapro, Avvigo Guidance System, Wavewriter Alpha Prime 16 |
| Glaxosmithkline, LLC. | $319.01 | 2019-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $264.64 | 2019-2024 | Fasenra, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $261.92 | 2022-2023 | |
| Exact Sciences Corporation | $181.84 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $150.91 | 2019-2021 | |
| Pfizer INC. | $147.83 | 2023-2024 | |
| Abbvie INC. | $146.50 | 2021-2024 | Vraylar, Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $104.26 | 2019-2022 | |
| Amgen INC. | $100.80 | 2019-2024 | Repatha, Otezla |
| Abbott Laboratories | $100.20 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $95.44 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.67 | 2019-2025 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $78.38 | 2019-2022 | |
| Mannkind Corporation | $76.44 | 2022 | |
| Lucid Diagnostics INC. | $60.89 | 2023 | |
| Allergan, INC. | $59.88 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $59.69 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.46 | 2019 | |
| Edwards Lifesciences Corporation | $33.92 | 2023 | Sapien 3 Ultra Resilia |
| Kowa Pharmaceuticals America, INC. | $33.92 | 2019 | |
| Idorsia Pharmaceuticals US INC | $33.67 | 2022-2023 | Quviviq |
| Shield Therapeutics INC | $27.16 | 2023 | Accrufer |
| Genentech USA, INC. | $21.07 | 2021 | |
| Esperion Therapeutics, INC. | $20.38 | 2024 | Nexletol |
| Medtronic, INC. | $18.47 | 2024 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $16.81 | 2021 | |
| Astellas Pharma US INC | $15.60 | 2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $14.85 | 2024 | Eliquis |
| Supernus Pharmaceuticals, INC. | $12.86 | 2023 | Qelbree |
| Dynavax Technologies Corporation | $12.86 | 2021 | |
| Eisai INC. | $12.64 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $12.54 | 2019 | |
| Currax Pharmaceuticals LLC | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Craft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.